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The target compounds, myr-(D-Orn)3-NH2 and its enantiomer 
myr-(L-Orn)3-NH2, were successfully made using solid phase 
peptide synthesis. Reverse phase preparative HPLC effectively 
purified the compounds. Mass spectometric analysis confirmed 
that the desired lipopeptides were obtained.  Furthermore, CD 
analysis distinguished the enantiomers. Finally, both 
lipopeptides exhibited better antimicrobial activity against 
S.aureus than E.coli. Although the L-lipopeptide was slightly 
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The researchers learned that developing a drug entails a lot of work. It is recommended 
that the stability of the L and D lipopeptides be checked. Furthermore, the activity of the 
lipopeptides against more resistant strains of bacteria and its antifungal activity could be 
tested. Finally, to test the viability of the lipopeptide as a drug, it is the hemolytic ability of 
the two lipopeptides could also be checked.  
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There is an urgent need to develop new antimicrobial agents due to the growing resistance 
of bacteria to commercial antibiotics. Lipopeptides are good drug candidates because their 
unique mechanism of destroying bacterial membrane makes them less susceptible to       
bacterial resistance. Recently, a number of ultrashort lipopeptides with cationic ornithine 
residues were designed and tested [1]. The tripeptide myr-(L-Orn)3-NH2 was found to have 
the best antimicrobial activity. Previous studies have shown that peptides with D-residues 
were more stable than those with L-residues [2]. This project aimed to evaluate the effect of  
incorporating D-amino acid residues into a known antimicrobial lipopeptide. The target 
compound, myr-(D-Orn)3-NH2 and its enantiomer, myr-(L-Orn)3-NH2, were synthesized,     
purified, characterized and tested for their anti-microbial activities against E. coli and           
S. aureus.   
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Table 1. MIC values in M of the lipopeptides 
and ampicillin against E.coli and S. aureus . 
Decreasing lipopeptide concentration (μM) 
21.6 
21.8 
[M+Na]+ 
592.4514 
C 
L Lipopeptide: 
C29N14O4H60  = 569.46 (calc) 
22.189 
21.898 
 
MIC    E. Coli S. aureus 
Myr-D-(Orn)3NH2    25.0    12.50 
Myr-L-(Orn)3NH2      12.5  6.25 
Ampicillin      50.0  1.56 
Decreasing lipopeptide concentration (μM) 
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Ampicillin 
L– lipopeptide 
D– lipopeptide 
Fig 2. UV spectra of L (top) and 
D- (bottom) lipopeptide depro-
tection solution 
Fig 3. HPLC chromatogram of crude 
L (top) and D- (bottom) lipopeptide 
using inertsil analytical column  
[M+H]+ 
570.4669 
L-amino acid 
[M+H]+ 
570.4717 
[M+Na]+ 
592.4514 
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more active than the D-lipopeptide, the results verify that these antimicrobial agents kill 
bacteria through non-specific intractions. With the added value of being more stable, myr-
(D-Orn)3-NH2 could prove to be an excellent drug candidate. 
Fig 6. Circular Dichroism spectra of myr-(L-Orn)3-NH2 
(dotted red line) and myr-(D-Orn)3-NH2 (solid black line) 
in water 
Fig 4. HPLC chromatogram of  L (top) 
and D- (bottom) lipopeptides after 
purification by preparative HPLC 
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D Lipopeptide: 
C29N14O4H60  = 569.46 (calc) 
Fig 5. Mass spectra of myr-(D-Orn)3-NH2  (top) and myr-(D-Orn)3-
NH2 (bottom) after purification by reverse phase preparative HPLC 
myr-(D-Orn)3-NH2 
myr-(L-Orn)3-NH2 
Fig 7. Broth dilution assay with S. aureus (left)  and E. coli (right)   
Fig 8. Mechanism of action of   
lipopeptide 
